Category Archives: Genetics

Genetics and animal science added to Fieldays Innovation Awards – Stuff.co.nz

Last updated16:31, May 23 2017

There are 71 entries in this years Innovation Awards at Fieldays including entries in animal science and genetics.

Genetics, animal science and chemical-based innovations are being addedfor the first time to the Fieldays Innovations Awardsthis year.

Competition organisers had expanded the criteriabecause of an increase of focus in thefields,Fieldays Innovations event manager Gail Hendricks said.

As a result, the competition has included two new judges tojudge the science behind theinnovations, she said.

Award organisershave received 71 entriesincluding innovations in fencing, irrigation, pasture management and animal health. Agricultural technology would also be on show, with several app-based innovations entered and a virtual reality innovation.

READ MORE: * Exciting fortunes ahead for the Waikato as it prepares for Fieldays *Steve Hansen talks rugby at Fieldays *Fieldays a chance to learn

The entries are displayed at theFieldays Innovations Centre, which showcases agricultural inventions and new applications with the potential to lead change in the rural sector.

The theme of Fieldaysis 'leading change'.Hendricks said the awards wereat the cutting edge of what was happening in agriculture, and the future of the industry.

"Originally, the Fieldays Innovation Awards was about widgets, gadgets and devices to improve farming, and now, more and more we are seeing how science and technology is impacting agriculture," Hendricks said.

The main entry categories are the Fieldays Prototype Award, Fieldays Launch NZ Award and Fieldays International Award.

Other awards up for grabs include categories for the bestYoung Inventor of the Year, technology innovation, research innovation, agri-innovation, intellectual propertyand commercialisation and intellectual property.

Hendricks said there was always public, business and agricultural industry interest in the innovation awards.

"The Innovations Centre is probably the busiest space at Fieldays and always attracts a lot of attention," said Hendricks. Every year, there is always broad media interest and the television breakfast shows broadcast from the Innovations Centre during Fieldays. The place is just buzzing."

Judges considerinventiveness, design and originality, the process of coming up with the innovation, commercial opportunities, intellectual property protection, technical viability and its benefit to New Zealand agriculture beforedeciding the winners.

The winners will be announced on June 15. Hendricks said they wouldreceive the kudos of winning the awards and any resulting publicity, but also access to expert support and business advice fromcompanies sponsoring each award.

Hendricks said entrants receiveda lot of value from entering the awards, as Fieldays provided access to a large group of potential customers and it gavethem a chance to do valuable market research.

Entrants also have exclusive access to business advisors, legal experts and product development consultants at a dedicated space in the Innovations Centre.

In addition, they have a chance to meet with potential investors at an invitation-only evening, Fieldays Innovations Capitalon June 15.

"The Innovations Centre is an exciting place to be at Fieldays. People visiting will see all sorts of interesting inventions and ideas that have practical and commercial application, to help streamline work on the farm."

-Stuff

Continue reading here:
Genetics and animal science added to Fieldays Innovation Awards - Stuff.co.nz

Local dairy farms find success using genetics – The Saratogian

NORTHUMBERLAND, N.Y. >> Nearly 200 people from 26 countries toured Saratoga County recently as part of a high-tech conference that has nothing to do with computer chip manufacturing or the semiconductor industry.

The group was comprised of dairy genetic consultants who visited local dairies to get a first-hand look at some of the industrys best animals.

The four-day event was hosted by Ohio-based Select Sires Inc., North Americas largest artificial insemination firm, and included stops at more than a dozen Capital Region farms including four in Saratoga County, recognized internationally as a hotbed for dairy genetics.

The goal of such efforts is healthier, higher producing, more profitable animals.

Advertisement

We work at having extremely elite genetics, said Jeff King, co-owner of Kings Ransom Farm in Northumberland. Less than 1 percent of dairy farms are as in tune as we are with their genetics. Its become part of our business model.

The group also visited Welcome Stock and Clear Echo farms in Bacon Hill, and Eildon Tweed Farm in Charlton.

We are all good friends, but theres also friendly competition, which makes us more successful, King said. Because were so concentrated here, it makes it easier for tour groups to visit, which is a big benefit for us.

Genetics has really been a passion of mine since I was a young kid, he said. Its a challenge to try to improve these animals with each successive generation. Its a joy for me to have a hand in making these decisions and producing a higher quality.

Each calf thats born has a genomic makeup, which identifies various traits. One animal might be a better milk producer, while another is more disease resistant or perhaps extra fertile.

The goal, when breeding, is studying the genomic traits of each animal, and pairing bulls and cows that are most apt to produce high-quality offspring, King said.

Visitors were on hand from places such as Mexico, Brazil, China, Australia, New Zealand and several European nations including Italy, Germany and France.

We sent them back home with information that can be used to improve cattle and dairy programs in their countries, said Rick Ver Beek, Select Sires dairy sire analyst.

His company buys high-quality bulls from farms and sells their semen to dairies around the world.

The industrys number one proven sire, based on milk production from its offspring, is a bull named Montross that came from Welcome Stock Farm. It now lives in Plain City, Ohio, where Select Sires is headquartered.

The breeding power of this bull is across all breeds, Ver Beek said. Its offspring have extremely high milk production and improved protein content; just really efficient, profitable, trouble-free animals.

In the face of domestic and global political turmoil, Ver Beek said it was refreshing to see people from so many countries come together, working for a common goal.

I think with agriculture in general theres tremendous camaraderie, he said. That common goal of feeding the world just kind of rings true.

More here:
Local dairy farms find success using genetics - The Saratogian

What Does it Mean to Be a Species? Genetics is Changing the Answer – Smithsonian

Ornithologist John Gould's illustrations of finches collected by Charles Darwin on the Galpagos Islands show the physical differences that the men relied on in dividing them into different species.

For Charles Darwin, "species" wasan undefinable term, "one arbitrarily given for the sake of convenience to a set of individuals closely resembling each other." That hasn't stopped scientists in the 150 years since then from trying, however. When scientists today sit down to study a new form of life, they apply any number ofmore than 70 definitionsof what constitutes a speciesand each helps get at a different aspect of what makes organisms distinct.

In a way, this plethora of definitions helps prove Darwins point: The idea of a species is ultimately a human construct. With advancing DNA technology, scientists are now able to draw finer and finer lines between what they consider species by looking at the genetic code that defines them. How scientists choose to draw that line depends on whether their subject is an animal or plant; the tools available; and the scientists own preference and expertise.

Now, as new species are discovered and old ones thrown out, researchers want to know: How do we define a species today? Lets look back at the evolution of the concept and how far its come.

Perhaps the most classic definition is a group of organisms that can breed with each other to produce fertile offspring, an idea originally set forthin 1942by evolutionary biologist Ernst Mayr. While elegant in its simplicity, this concept has since come under fire by biologists, who arguethat it didn't apply to many organisms, such as single-celled ones that reproduce asexually, or those that have been shown to breed with other distinct organisms to create hybrids.

Alternativesarose quickly. Some biologists championed an ecologicaldefinition that assigned species according to the environmental niches they fill (this animal recycles soil nutrients, this predator keeps insects in check). Others asserted that a species was a set of organisms with physical characteristics that were distinct from others (the peacock's fanned tail, the beaks of Darwin's finches).

The discovery of DNA's double helix prompted the creation of yet another definition, one in which scientists could look for minute genetic differences and draw even finer lines denoting species. Based ona 1980 bookby biologists Niles Eldredge and Joel Cracraft, under the definition of a phylogenetic species, animal species now can differ by just 2 percent of their DNA to be considered separate.

"Back in 1996, the world recognized half the number of species of lemur there are today," says Craig Hilton-Taylor, who manages the International Union for the Conservation of Nature's Red Listof threatened species. (Today there are more than 100 recognized lemur species.) Advances in genetic technology have given the organization a much more detailed picture of the world's species and their health.

These advances have also renewed debates about what it means to be a species, as ecologists and conservationistsdiscover that many species that once appeared singularare actually multitudes. Smithsonian entomologistJohn Burnshas used DNA technology to distinguish a number of so-called "cryptic species"organisms that appear physically identical to a members of a certain species, but have significantly different genomes. In a2004 study, he was able to determine that a species of tropical butterfly identified in 1775 actually encompassed 10 separate species.

In 2010, advanced DNA technology allowed scientists to solve an age-old debate over African elephants. By sequencing therarer and more complex DNA from the nuclei of elephant cells,instead of the more commonly used mitochondrial DNA, they determined thatAfrican elephants actually comprised two separate speciesthat diverged millions of years ago.

"You can no more call African elephants the same species as you can Asian elephants and the mammoth," David Reich, a population geneticist and lead author on the study, told Nature News.

In the wake of these and other paradigm-shifting discoveries, Mayrs original concept is rapidly falling apart. Those two species of African elephants, for instance, kept interbreeding as recently as 500,000 years ago. Another example falls closer to home: Recent analyses of DNA remnants in the genes of modern humans have found that humans and Neanderthalsusually thought of as separate species thatdiverged roughly 700,000 years agointerbred as recently as 100,000 years ago.

So are these elephants and hominidsstill separate species?

This isn't just an argument of scientific semantics. Pinpointing an organism's species is critical for any efforts to protect that animal, especially when it comes to government action. A species that gets listed on the U.S. Endangered Species Act, for example,gains protectionfrom anydestructive actions from the government and private citizens.These protections would be impossible to enforce without the ability to determine which organisms are part of that endangered species.

At the same time,advances in sequencing techniques and technologyare helping todays scientists better piece together exactly which species are being impacted by which human actions.

"We're capable of recognizing almost any species [now]," saysMary Curtis, a wildlife forensic scientist who leads the genetics team at the U.S. Fish and Wildlife Service'sForensics Laboratory. Her lab is responsible for identifying any animal remains or products that are suspected to have been illegally traded or harvested. Since adopting DNA sequencing techniques more than 20 years ago, the lab has been able to make identifications much more rapidly, and increase the number of species it can reliably recognize by the hundreds.

"A lot of the stuff we get in in genetics has no shape or form," Curtis says. The lab receives slabs of unidentified meat, crafted decorative items or even the stomach contents of other animals. Identifying these unusual items is usually out of the reach of taxonomic experts using body shape, hair identification and other physical characteristics. "We can only do that with DNA," Curtis says.

Still, Curtis, who previously studied fishes, doesn't discount the importance of traditional taxonomists. "A lot of the time we're working together," she says. Experienced taxonomists can often quickly identify recognizable cases, leaving the more expensive DNA sequencing for the situations that really need it.

Not all ecologists are sold on these advances. Some express concerns about "taxonomic inflation," as the number of species identified or reclassified continues to skyrocket. They worry that as scientists draw lines based on the narrow shades of difference that DNA technology enables them to see, the entire concept of a species is being diluted.

"Not everything you can distinguish should be its own species," as German zoologist Andreas Wiltingtold the Washington Post in 2015. Wilting hadproposed condensing tigers into just two subspecies, from the current nine.

Other scientists are concernedabout the effects that reclassifying once-distinct species can have on conservation efforts. In 1973, the endangered dusky seaside sparrow, a small bird once found in Florida, missed out on potentially helpful conservation assistance by beingreclassified as a subspeciesof the much more populous seaside sparrow . Less than two decades later, the dusky seaside sparrow was extinct.

Hilton-Taylor isnt sure yet when or how the ecological and conservation communities will settle on the idea of a species. But he does expect that DNA technology will have a significant impacton disrupting and reshaping the work of those fields. Lots of things are changing, Hilton-Taylor says. That's the world we're living in.

This uncertainty is in many ways reflective of the definition of species today too, Hilton-Taylor says. The IUCN draws on the expertise of various different groups and scientists to compile data for its Red List, and some of those groups have embraced broader or narrower concepts of what makes a species, with differing reliance on DNA. There's such a diversity of scientists out there, Hilton-Taylor says. We just have to go with what we have.

Original post:
What Does it Mean to Be a Species? Genetics is Changing the Answer - Smithsonian

Do we know enough about genetics for personalized DNA tests to improve our health, fitness? – Genetic Literacy Project

The latest health and fitness trend involves taking a DNA test to find out more about how our bodies respond to different types of food and exercise.

A growing number of start-ups, such as 23andMe, FitnessGenes, UBiome, DNAFit, Orig3n and Habit, are moving into this space, promising that mail-order genetic tests can change your life for the better.

Avi Lasarow, chief executive of DNAFit, explains that everything about who we are is the unique combination of what we are born with our genetics and how we live our environment.

The biggest environment factor that we can control in our day-to-day lives is our diet, he says, so by understanding more about the static part, the genetics, we can better tweak the bit in our control.

[S]ome genetic experts are concerned that the efficacy of such kits may be overhyped.

I do think that the amount of useful information that personalised health tests can offer is very limited at present because we still know very little about the effect of most SNPs [genetic variations called single nucleotide polymorphisms] and other types of genetic variation on a persons health, [says Dr Jess Buxton, a geneticist at University College London.]

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Can knowing your genetic make-up lead to a healthier life?

See the rest here:
Do we know enough about genetics for personalized DNA tests to improve our health, fitness? - Genetic Literacy Project

Seattle Genetics cancels Immunomedics deal – Chemistry World (subscription)

US biotechnology firms Seattle Genetics and Immunomedics have broken off their planned licensing deal for Immunomedics experimental cancer antibody IMMU-132 (sacituzumab govitecan).

The deal had been hampered by legal action from Immunomedics shareholders, including investment fund venBio. Immunomedics has proposed to settle this litigation following cancellation of the deal. As part of the settlement agreement, Immunomedicss chief executive, Cynthia Sullivan, will leave the company. Founder David Goldenberg will also step down as chief science officer, although he will retain a seat on the board. Behzad Aghazadeh from venBio has assumed the role of Chairman.

View original post here:
Seattle Genetics cancels Immunomedics deal - Chemistry World (subscription)

Thanks to Genetic Testing, Everyone Could Soon Have a Pre-Existing Condition – Slate Magazine

A quick cheek swab and youre well on your way to learning quite a bit about your genetic risk factors.

fotoquique/iStock

As currently written, the American Health Care Act allows states to opt out of the popular Obamacare provision that bans insurers from discriminating against people with pre-existing conditions. Twenty-seven percent of adult Americans under the age of 65 have a declinable pre-existing condition, according to the Kaiser Family Foundation, and if the AHCA becomes law, any number of them could become uninsured. The guiding GOP arithmetic takes as a given that people should pre-emptively pony up for conditions beyond their controlincluding, yes, having a second X chromosome. Millions more have conditionsfrom asthma to the ever-inconvenient urinary tract infectionthat could also jack up the rate of coverage, making insurance prohibitively expensive.

What their calculations dont yet consider are the could-be conditions embedded in our DNA. Our genomes provide a window into scores of genetic risk factors that have yet to present as full-fledged pre-existing conditions. If the GOP insists that people can be charged differently depending on their current health, whats to say theyll stop short of asserting that we could be charged according to our genomes?

The personal genetics revolution is well-underway. More Americans than ever have access to the information contained in their genetic material. When the Affordable Care Act passed in 2010, the cost of sequencing the 3 billion As, Cs, Gs, and Ts that comprise the human genome rang in at $50,000. Today, that price tag has plummeted to $1,000 with promises of a $100 genome in the near future. Already a mere $99 and a dab of spittle will give consumers a good sense of their genetic risk factors from private genetic testing company 23andMe. Last month, the company received Food and Drug Administration approval to test for predispositions to 10 medical conditions. And even before that came through, customers could upload the raw DNA data generated by 23andMe into interpretation only services like Promethease for a DIY disease risk assessment.

And thats just personal use of genetic informationthe current $1,000 price tag means its already accessible in many medical settings. The question now turns to how the data deluge brought on by the genomics age will be used. Personal genetics can empower patients, doctors, and researchers to make more informed decisions around health care. But while this information could help us make better medical choices, it could also be used to fine-tune insurance algorithms, calculating premiums on a sliding scale of genetic risk.

Americans saw this trade-off coming. The Human Genome Project spurred concerns around genetic discrimination in the 1990s. Over a decade before Obamacares pre-existing conditions protections, patient and civil rights organizations came together to press for protections against genetic discrimination. Thirteen years of advocacy efforts led to the bipartisan passage of the Genetic Information Nondiscrimination Act of 2008. GINA prohibits employers and health insurers from using genetics to influence hiring decisions and insurance coverage.

The legislation was celebrated as the first major civil-rights bill of the century. It eased concerns around genetic discrimination to ultimately encourage people to take advantage of emerging genetic technologies and therapies. GINAs protections helped advance genome research, and today millions of Americans have submitted genetic samples for testing. A government-funded $215 million Precision Medicine Initiative is now underway with the goal of collecting genetic and health data from over 1 million Americans to better inform biomedical research.

That means millions of genotypes that can be used by clinicians and researchers to home in on and characterize genes linked to specific diseases. That also means millions of genotypes that could be factored into the underwriting calculus that prioritizes profits over patients.

Whats to say the GOP will stop short of asserting that we could be charged according to our genomes?

Life, disability, and long-term care insurance, which are not covered under GINAs provisions, already use genetic testing results to deny coverage to otherwise healthy individuals. And when it comes to health insurance, GINA isnt perfect. The legislation only protects people who are genetically predisposed to a disease if they are asymptomatic. Once a person begins showing symptoms, GINA no longer matters. But for a while, Obamacare closed that loophole. When it was enacted, personal genetics was still in its infancy23andMe had less than 50,000 customers at a price tag of $999, and AncestryDNA had yet to launch. So in the years since the ACAs passage, shoring up protections against genetic discrimination has received little legislative attention.

Obamacare repeal reopens the gray area between genetic predisposition and a pre-existing condition. The AHCAs MacArthur amendment would require that states opting out of Obamacares pre-existing conditions rule set up high-risk pools for sick people who incur higher medical costs. But what sick actually means is increasingly up for debate. Does a BRCA1 mutation, which portends a 55 percent to 65 percent risk of developing breast cancer by the age of 70, count as a pre-existing condition when youre 30? When youre 60?

DNA doesnt encode certain destiny: Carrying the BRCA1 mutation offers no more clarity than the percentage given above. But without the ACA, GINA is the only thing stopping insurance companies from practicing genetic determinism when they decide what conditions warrant higher premiums or coverage denial. Republicans, who control every branch of government, have shown that they believe different people should be required to pay different amounts on the basis of what essentially amounts to dumb luck. And we already know they have little interest in regulating corporate interests. Besides, nobody dies because they don't have access to health care, remember?

Even with GINA and Obamacare protections still in place, Americans remain wary of participating in whole-genome sequencing studies, citing fears of discrimination from life insurance companies. Their skepticism is warranted: For all its attributes, the ACA paradoxically opened a GINA loophole by encouraging employer health care plans to offer discounts for participating in workplace wellness programs. GOP lawmakers recently seized on this idea, introducing legislation to compel employees to share genetic test results with their employers.

We already know the current government is not much interested in sciencebut if that science involves calculating maximizing profit margins at the expense of patient empowerment, they just might perk up.

Read the original here:
Thanks to Genetic Testing, Everyone Could Soon Have a Pre-Existing Condition - Slate Magazine

Data from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor … – GlobeNewswire (press release)

May 18, 2017 06:00 ET | Source: NewLink Genetics Corporation Updated NewLink Infographic for ASCO and EHA.pdf

AMES, Iowa, May 18, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic agents for patients with newly diagnosed acute myelogenous leukemia (AML), is now available on the website of the European Hematology Association (EHA) Annual Congress.

An infographic accompanying this announcement is available athttp://www.globenewswire.com/NewsRoom/AttachmentNg/8a3b562f-28b3-4526-baaf-95974cd8eb4f

These data to be presented at the EHA Congress further highlight clinical results presented at AACR in April and to be presented at ASCO in June, supporting the hypothesis that the IDO pathway is central to immune suppression in cancer, said Charles J. Link, Jr., M.D., Chief Executive Officer and Chief Scientific Officer. NewLink Genetics has two separate and distinct types of IDO pathway inhibitors in clinical development. Indoximod, which is wholly owned by NewLink Genetics, has a proposed differentiated mechanism within the IDO pathway and acts as a tryptophan mimetic having a direct effect on immune cells to reverse immune suppression used by cancer to protect itself.

Indoximod in combination with chemotherapeutic agents

Initial results from the Phase 1b portion of a Phase 1b/randomized Phase 2a trial of indoximod in combination with chemotherapeutic agents, idarubicin and cytarabine, for patients with newly diagnosed AML will be presented as an e-poster (Abstract number E-912) by Ashkan Emadi, M.D., Ph.D., Associate Professor of the University of Maryland Greenebaum Comprehensive Cancer Center, at EHA in Madrid on Friday, June 23, 2017, 9:30 AM to Saturday, June 24, 7:00 PM CET and is titled: Indoximod in Combination with Idarubicin and Cytarabine for Upfront Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Phase 1 Report.

This study uses a conventional remission induction and consolidation protocol for patients with newly diagnosed AML. Indoximod is given orally starting on day 8 of induction onward. The Phase 1 portion evaluated three dose levels of indoximod (600 mg, 1000 mg, 1200 mg) in combination with the standard of care 7+3 chemotherapy. Twelve patients were enrolled, as of March 1, 2017. The results indicate indoximod does not appear to add significant toxicity to standard remission induction and consolidation therapy for patients with newly diagnosed AML. Initial data suggest a low rate of minimal residual disease (MRD-neg) after one cycle of induction chemotherapy.

Nicholas N. Vahanian, M.D., President and Chief Medical Officer added, Importantly, these data support further clinical investigation of our IDO pathway inhibitors in combination with currently available therapies, such as chemotherapy for patients with newly diagnosed Acute Myeloid Leukemia (AML).

Key findings presented from the study include:

About Indoximod Indoximod is an investigational, orally available small molecule targeting the IDO pathway. The IDO pathway is one of the key immuno-oncology targets involved in regulating the tumor microenvironment and immune escape.

NewLink Genetics is currently evaluating indoximod in multiple combination studies for patients with various types of cancer including melanoma, acute myeloid leukemia, pancreatic cancer and prostate cancer.

About NewLink Genetics Corporation NewLink Geneticsis a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.NewLink Genetics'product candidates are designed to harness multiple components of the immune system to combat cancer.For more information, please visit http://www.newlinkgenetics.com.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties.All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.These forward-looking statements include, among others, statements about results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact.Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics Annual Report on Form 10-K for the year endedDecember 31, 2016and other reports filed with theU.S. Securities and Exchange Commission(SEC).The forward-looking statements in this press release represent NewLink Genetics views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change.However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.

Related Articles

NewLink Genetics Corporation

Ames, Iowa, UNITED STATES

http://www.linkp.com

Updated NewLink Infographic for ASCO and EHA.pdf

FILE URL | Copy the link below

NewLink Genetics Corporation Logo

LOGO URL | Copy the link below

Formats available:

Continue reading here:
Data from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor ... - GlobeNewswire (press release)

Data from Clinical Studies of NewLink Genetics’ Two Distinct IDO … – GlobeNewswire (press release)

May 17, 2017 17:05 ET | Source: NewLink Genetics Corporation NewLink Infographic ASCO.pdf

AMES, Iowa, May 17, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with other agents, are now available on the website of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

An infographic accompanying this announcement is available athttp://www.globenewswire.com/NewsRoom/AttachmentNg/b945495b-6286-4184-881f-b4ea49aa46b4

The IDO pathway is a key immuno-oncology target and NewLink Genetics has two separate and distinct IDO pathway inhibitors in clinical development.Indoximod, which is wholly owned by NewLink Genetics, has a proposed differentiated mechanism within the IDO pathway and acts as a tryptophan mimetic having a direct effect on immune cells to reverse immune suppression used by cancer to protect itself. Navoximod is our direct enzymatic inhibitor of IDO and is partnered with Genentech/Roche, said Charles J. Link, Jr., M.D., Chief Executive Officer and Chief Scientific Officer of NewLink Genetics.

Indoximod in combination with the therapeutic cancer vaccine, PROVENGE

Results from a randomized, double-blind, placebo-controlled, multi-institutional Phase 2 investigator initiated study with indoximod in combination with the therapeutic cancer vaccine, PROVENGE (sipuleucel-T), for patients with metastatic castration resistant prostate cancer will be presented as a poster (Abstract number 3066) by Gautam Gopalji Jha, M.D., Adjunct Assistant Professor, Division of Hematology and Oncology, University of Minnesota, at ASCO in Chicago on Monday, June 5, 2017, 8:00 a.m. 11:30 a.m. CT, titled, A phase 2 randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC).

In the study, forty-six patients were randomized into two arms to receive either twice daily oral indoximod (n=22) or placebo (n=24) for 6 months beginning the day after the third and final PROVENGE infusion. Conclusions indicate that treatment with the IDO pathway inhibitor, indoximod, post PROVENGE therapy, leads to significant improvement in radiographic progression free survival (rPFS) when compared to placebo and is well-tolerated.

Key findings presented from the study include:

These data further support the hypothesis that targeting the IDO Pathway in combination with a broad backbone of treatment regimens including chemotherapy, anti-PD-1 antibodies and therapeutic vaccines across multiple indications has the potential to provide meaningful clinical benefit without compromising tolerability, commented Nicholas N. Vahanian, M.D., President and Chief Medical Officer of NewLink Genetics.

Navoximod in combination with TECENTRIQ (atezolizumab) in multiple solid tumors

Initial data from a Phase 1b dose-escalation study of navoximod in combination with TECENTRIQ for patients with locally advanced or metastatic solid tumors conducted by our partner, Genentech/Roche, will be presented in an oral presentation (Abstract number 105) by Howard A. Skip Burris, III, M.D., President Clinical Operations and Chief Medical Officer, Sarah Cannon Research Institute, at ASCO in Chicago on Sunday, June 4, 2017, 10:24 a.m. CT. The presentation is titled, A phase 1b dose-escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients with locally advanced or metastatic solid tumors.

This Phase 1b, open-label, dose-escalation study is designed to characterize safety and tolerability. Secondary objectives include identifying a maximum tolerated dose (MTD) and recommended Phase 2 dose, and evaluating pharmacokinetics, pharmacodynamics, and anti-tumor activity. Patients were given TECENTRIQ (1200 mg IV every 3 weeks) and escalating doses of navoximod (orally twice daily, for 21 days) using a standard 3+3 design. Initial results from this study (n=52, non-selected heterogeneous population during the dose escalation) found the combination was generally well-tolerated, with peripheral IDO1 modulation, and some early activity signals. Patients were previously treated with prior systemic therapies with a median number of 3 and a range of 1-9. Two patients also received prior immunotherapy.

The design of the trial includes the initial dose-escalation phase reported in this abstract, followed by disease-specific expansion cohorts (enrollment target is 305 patients) for patients with select tumor types including non-small-cell lung cancer (NSCLC), renal cell cancer (RCC), urothelial bladder cancer (UBC), triple negative breast cancer (TNBC), to further evaluate safety, response, and peripheral and tumor pharmacodynamics. Updates for this study will continue to be reported by Genentech/Roche.

Dr. Vahanian continued, We are encouraged by the clinical profile for the combination of navoximod and atezolizumab from the first phase of this combination trial and look forward to the data for the disease-specific expansion cohorts which are currently accruing patients.

About NewLink Genetics Corporation

NewLink Geneticsis a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.NewLink Genetics'product candidates are designed to harness multiple components of the immune system to combat cancer.For more information, please visit http://www.newlinkgenetics.com.

PROVENGE is a registered trademark of Dendreon/Valeant Pharmaceuticals International, Inc. TECENTRIQ is a registered trademark of Genentech, Inc.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties.All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.These forward-looking statements include, among others, statements about results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact.Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics Annual Report on Form 10-K for the year endedDecember 31, 2016and other reports filed with theU.S. Securities and Exchange Commission(SEC).The forward-looking statements in this press release represent NewLink Genetics views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change.However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.

Related Articles

Read more from the original source:
Data from Clinical Studies of NewLink Genetics' Two Distinct IDO ... - GlobeNewswire (press release)

Genetic Health Information Network Summit Will Address Precision Medicine Challenges – PR Newswire (press release)

Unique in both its broad engagement of healthcare stakeholders and its focus on practical solutions to real-world challenges in precision medicine, the invitation-only event will convene leading health plans, clinicians, hospital systems, researchers, policy makers, laboratories, technology vendors and pharmaceutical companies, as well as patients and advocates.

Together, these stakeholders will work to develop action plans to:

"This event is not about simplistic answers, nor debate for its own sake. The goal is to engage in an open, honest dialog that produces clear action plans to improve the Genetic Health Information Network together," said Gillian Hooker, PhD, Concert's vice president of clinical development. "Ultimately, we all want a healthcare system that delivers on the promise of precision medicine to every patient who needs it. In order to do that, we need to work together. We're committed to doing our part to make that happen, both in preparation for the summit, and in facilitating action that will follow it."

The event's organizing committee includes members from across the healthcare landscape. They include:

"Despite the tremendous promise of precision medicine to improve human health, the field suffers from a dearth of data and the digital infrastructure to effectively study the impact of precision diagnostics, drugs and other interventions on healthcare outcomes," said Carlos Bustamante, PhD. "The collaboration represented by this summit is exactly what's needed to change that."

More information on the Summit can be found at http://www.geneticnetworksummit.com.

To advance the industry-wide discussion about improving the Genetic Health Information Network, Concert Genetics published a white paper earlier this year on the state of the Genetic Health Information Network and top opportunities to connect and enhance the network to better integrate precision medicine into the healthcare system. More on that document can be found here: http://www.concertgenetics.com/network.

About Concert GeneticsConcert Genetics provides software and analytic tools to connect, simplify and unify the world of genetic testing for hospital and health systems, clinicians, health plans, labs and governing organizations. Concert's unique applications are built on a market-leading database that combines its index of the entire U.S.-based clinical genetic testing market today more than 70,000 testing products with other enriched data, such as genetic testing claims data from more than 100 million insured members. This data powers the leading genetic test search tool, specialized industry benchmarking and nuanced analysis of market dynamics. Concert aims to connect the disparate stakeholders in the healthcare community to help unlock the full potential of genetic testing for delivering precision medicine. Learn more at http://www.ConcertGenetics.com.

Media Contact:Erin George erin@lovell.com 615-946-9914

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genetic-health-information-network-summit-will-address-precision-medicine-challenges-300459834.html

SOURCE Concert Genetics

http://www.ConcertGenetics.com

Read the original here:
Genetic Health Information Network Summit Will Address Precision Medicine Challenges - PR Newswire (press release)

Turns Out Nazis Have Some Pretty Wrong Views About Genetics – New York Magazine

Photo: Stefano Bianchetti/Getty Images

Most people tend to have a certain idea about their heritage: that they simply are, well, whatever they are. Scottish or German or Nigerian or whatever else. Maybe theres some other stuff mixed in there, sure, but most people have a sense that theyre from one particular place, and thats where their culture and maybe some of their values originates.

Naturally, DNA tells a more complicated story, and a new article in Science by Ann Gibbons very usefully punctures a bunch of myths, some of them pretty harmful, about human ancestry. The vast majority of us are mutts, it turns out, and oftentimes the genetic heritage we think we have bears little resemblance to whats actually hiding in our chromosomes.

Gibbons starts the article by quoting a German neo-Nazi, doing what neo-Nazis tend to do, expressing alarm about the arrival of Syrian refugees and the prospect of them sullying his precious German genetic heritage.

From there she swiftly moves to the main point of the article:

Using revolutionary new methods to analyze DNA and the isotopes found in bones and teeth, scientists are exposing the tangled roots of peoples around the world, as varied as Germans, ancient Philistines, and Kashmiris. Few of us are actually the direct descendants of the ancient skeletons found in our backyards or historic homelands. Only a handful of groups today, such as Australian Aborigines, have deep bloodlines untainted by mixing with immigrants.

That aforementioned notion of German purity, to take one example, comes from a Nazi mangling of an already somewhat thinly sourced story about a Germanic fighter named Arminius who supposedly led a rebellion against the Romans 2,000 years ago the Nazis portrayed him as a blond-haired member of a supposed master race.

Now, it shouldnt be surprising that Nazis dont have a particularly sophisticated grip on genetics. But this article is still an interesting, comprehensive look at where researchers are in their quest to understand humanitys genetic legacy. And the short, also-unsurprising answer is: Weve moved around a lot and mixed it up a lot.

Gibbonss piece also usefully complicates the notion of genetic superiority, highlighting just how historically contingent this idea is. For example, she writes of two different groups that collided at one point and produced offspring: The unions between the Yamnaya and the descendants of Anatolian farmers catalyzed the creation of the famous Corded Ware culture, known for its distinctive pottery impressed with cordlike patterns According to DNA analysis, those people may have inherited Yamnaya genes that made them taller; they may also have had a then-rare mutation that enabled them to digest lactose in milk, which quickly spread It was a winning combination. The Corded Ware people had many offspring who spread rapidly across Europe. Today, of course, very few people are aware of the Corded Ware culture a group that was very much, for random genetic reasons, in the right place at the right time.

For most of human history, humans havent been great at recording history accurately, so along the way many cultures have developed myths about their lineage, about who was where, when. A lot of the time, the straightforward stories people tell to be proud of themselves and their ancestors are oversimplifications, at best. In the worst cases, these myths lead to ideologies like nationalism.

Its important to understand the appeal and functional role of bloodline myths, of course: This group could sully our bloodlines packs a bit more of a visceral punch than I am nervous this new group will cause the neighborhood to change. Because people dont tend to really understand genetics, and because the subject efficiently taps into many peoples most intimate feelings about disgust and purity, such talk can be a useful way to rile people up, almost always for the worse. Which is why its important to understand just how superficial it really is.

The psychology of how we choose who to leave out.

Research suggests that sexism in hiring cant explain the entire gender gap in leadership positions theres other stuff going on, too.

Just about everyone, everywhere, is a complicated mutt, and stories about pure bloodlines are almost always false.

Labels like organic and natural are impossibly vague and often misleading.

Most adults can do a decent job of understanding other peoples internal mental states. Not the leader of the free world.

Or its about to be, at least. Thats just the life cycle of any fad.

It might seem counterintuitive to advertise a place for injection-drug users to shoot up, but theres smart public-health reasoning behind the idea.

Not exactly, but theres some merit to the myth.

Time to find another hangover remedy.

A realization about monogamy that should make anyone getting married feel a little more hopeful.

Its a mixed bag.

The science behind a common-sense piece of advice.

Giving your mind time to wander is a key part of creativity.

Theres a bit of dissent within the American Psychological Association about the role of video games in contributing to violence.

A new TEDx video sums up the research of Bella DePaulo, a social psychologist who has been chipping away at the many myths surrounding marriage.

No matter how long they live in a loud urban environment.

The WHO and the CDC offer different recommendations for proper handwashing technique. Which is right?

Drinking with the author of Cork Dork, a new book about the obsessive world of wine.

A new study explains.

During the current fixation on the intersection of design and psychology, its worth remembering what workers are going through at the moment.

Here is the original post:
Turns Out Nazis Have Some Pretty Wrong Views About Genetics - New York Magazine